Hashemi-Sadraei N - Search Results

1

Expression of LC3B and FIP200/Atg17 in brain metastases of breast cancer.

Hashemi-Sadraei N, Müller-Greven GM, Abdul-Karim FW, Ulasov I, Downs-Kelly E, Burgett ME, Lauko A, Qadan MA, Weil RJ, Ahluwalia MS, Du L, Prayson RA, Chao ST, Budd TG, Barnholtz-Sloan J, Nowacki AS, Keri RA, Gladson CL. Hashemi-Sadraei N, et al. J Neurooncol. 2018 Nov;140(2):237-248. doi: 10.1007/s11060-018-2959-5. Epub 2018 Aug 9. J Neurooncol. 2018. PMID: 30094720

2

Efficacy and patient-reported outcomes with dose-intense temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma: a phase II multicenter study.

Ahluwalia MS, Xie H, Dahiya S, Hashemi-Sadraei N, Schiff D, Fisher PG, Chamberlain MC, Pannullo S, Newton HB, Brewer C, Wood L, Prayson R, Elson P, Peereboom DM. Ahluwalia MS, et al. J Neurooncol. 2015 Mar;122(1):111-9. doi: 10.1007/s11060-014-1684-y. Epub 2014 Dec 23. J Neurooncol. 2015. PMID: 25534576 Clinical Trial.

3

Lung cancer treatment outcomes in recipients of lung transplant.

Du L, Pennell NA, Elson P, Hashemi-Sadraei N. Du L, et al. Transl Lung Cancer Res. 2015 Dec;4(6):784-91. doi: 10.3978/j.issn.2218-6751.2015.12.08. Transl Lung Cancer Res. 2015. PMID: 26798588 Free PMC article.

4

High UDG and BRCA1 expression is associated with adverse outcome in patients with pemetrexed treated non-small cell lung Cancer.

Hashemi Sadraei N, Feng Y, Du L, Fu P, Haque S, Dowlati A, Gollamudi J, Pennell NA, Mekhail T, Avril S, Farver C, Gerson SL, Sharma N. Hashemi Sadraei N, et al. Lung Cancer. 2018 Dec;126:48-54. doi: 10.1016/j.lungcan.2018.08.011. Epub 2018 Aug 13. Lung Cancer. 2018. PMID: 30527192

5

Advanced non-small cell lung cancer (NSCLC): maintenance therapy for all?

Hashemi-Sadraei N, Pennell NA. Hashemi-Sadraei N, et al. Curr Treat Options Oncol. 2012 Dec;13(4):478-90. doi: 10.1007/s11864-012-0209-1. Curr Treat Options Oncol. 2012. PMID: 22972369

6

Chemotherapy in newly diagnosed primary central nervous system lymphoma.

Hashemi-Sadraei N, Peereboom DM. Hashemi-Sadraei N, et al. Ther Adv Med Oncol. 2010 Jul;2(4):273-92. doi: 10.1177/1758834010365330. Ther Adv Med Oncol. 2010. PMID: 21789140 Free PMC article.

7

Profile of pembrolizumab in the treatment of head and neck squamous cell carcinoma: design development and place in therapy.

Haque S, Yellu M, Randhawa J, Hashemi-Sadraei N. Haque S, et al. Drug Des Devel Ther. 2017 Aug 31;11:2537-2549. doi: 10.2147/DDDT.S119537. eCollection 2017. Drug Des Devel Ther. 2017. PMID: 28919706 Free PMC article. Review.

8

Aberrant signaling pathways in squamous cell lung carcinoma.

Shi I, Hashemi Sadraei N, Duan ZH, Shi T. Shi I, et al. Cancer Inform. 2011;10:273-85. doi: 10.4137/CIN.S8283. Epub 2011 Nov 21. Cancer Inform. 2011. PMID: 22174565 Free PMC article.

9

An Open-Label Phase II Trial of Bevacizumab plus Docetaxel and Gemcitabine in Advanced, Previously Untreated Nonsquamous Non-Small Cell Lung Cancer.

Patil PD, Shapiro M, Hashemi Sadraei N, Pennell NA. Patil PD, et al. Oncologist. 2019 Apr;24(4):457-e126. doi: 10.1634/theoncologist.2018-0857. Epub 2019 Jan 2. Oncologist. 2019. PMID: 30602615 Free PMC article. Clinical Trial.

10

Comparative molecular profiling of HPV-induced squamous cell carcinomas.

Koncar RF, Feldman R, Bahassi EM, Hashemi Sadraei N. Koncar RF, et al. Cancer Med. 2017 Jul;6(7):1673-1685. doi: 10.1002/cam4.1108. Epub 2017 May 29. Cancer Med. 2017. PMID: 28556593 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

33 results

Search Page